Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nasdaq  >  Dendreon Corporation       US24823Q1076

End-of-day quote. End-of-day quote  - 06/11
0.0325 USD   -4.41%
02/20DJValeant Approved to Buy Dendreon Assets for $495 Million
02/20 Drugmaker Valeant close to buying Salix - source
02/12 VALEANT SECURES : Bloomberg
 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2014 299 M
EBIT 2014 -57,0 M
Net income 2014 -107 M
Debt 2014 -
Yield 2014 -
Sales 2015 327 M
EBIT 2015 -56,8 M
Net income 2015 -73,1 M
Debt 2015 421 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 0,02x
EV / Sales 2015 1,30x
Capitalization 5,40 M
More Financials
Company
Dendreon Corp. is a biotechnology company, which focuses on discovery, development and commercialization of novel therapeutics that improves cancer treatment options for patients.The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular... 
More about the company
Surperformance© ratings of Dendreon Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on DENDREON CORPORATION
06/10 DENDREON : Regulation FD Disclosure, Change in Directors or Principal Officers (..
06/03 DENDREON : Material Modification to Rights of Security Holders, Regulation FD Di..
06/02 DENDREON : Regulation FD Disclosure (form 8-K)
05/21 DENDREON : Regulation FD Disclosure, Other Events, Financial Statements and Exhi..
04/29 DENDREON : Valeant Pharmaceuticals Reports First Quarter 2015 Financial Results
04/21 DENDREON : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K..
04/17 DENDREON : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K..
04/08 DENDREON : Other Events (form 8-K)
More news
Sector news : Biotechnology & Medical Research - NEC
04:06p INTREXON : Oragenics Reports Positive In Vivo Antibiotic Efficacy Data in Critic..
07:01a ISIS PHARMACEUTICALS' : Second Quarter 2015 Financial Results Conference Call (W..
06:18a UNITED THERAPEUTICS : beats 2Q profit forecasts
More sector news : Biotechnology & Medical Research - NEC
Comments 
Advertisement
Chart DENDREON CORPORATION
Duration : Period :
Dendreon Corporation Technical Analysis Chart | US24823Q1076 | 4-Traders
Full-screen chart
Technical analysis trends DENDREON CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions